March 7, 2023—JAL Therapeutics, an Irvine-CA based preclinical stage life sciences company focused on drug development for the treatment of Alzheimer’s disease (AD) and other chronic conditions, has been accepted into the California Life Sciences FAST program.
California Life Sciences (CLS) is the state’s most influential and impactful life sciences membership organization, advocating for companies from startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As an accelerator program by CLS, FAST California fosters innovation by providing a curated advisory team of industry experts for each program member to perfect business models, assess strategic focus, maximize IP and help develop a milestone and scale-up plan to exit.
FAST is supported by sponsors including AbbVie, DLA Piper, Cooley, Hogan Lovells, Johnson & Johnson Innovation, Keck School of Medicine of USC (MESH Academy), MedTech Color, MedTech Innovator, and Women In Bio. Twelve therapeutic and MedTech startups were selected to take part in the FAST California spring cohort, culminating with an event called Innovation Showcase on June 21 in San Francisco. JAL Therapeutics and other companies in the cohort will pitch to an audience of potential investors and collaboration partners at the event.
“It’s an honor for JAL Therapeutics to be in the CLS FAST Advisory program,” said Kensaku Nakayama, CEO. “Our company’s momentum in drug development for AD and other chronic conditions is palpable, and this program will only serve to accelerate our progress. We’re looking forward to collaborating with our advisory team as we refine approaches to engage with strategic investors and potential licensing partners.”
Since its inception, the CLS FAST Advisory Program has been associated with 37 Series A investments among participating startups, totaling $2.5 billion in funds raised. For more information about the California Life Sciences Fast Advisory Program, visit: https://www.califesciences.org/fast-program/
About JAL Therapeutics: JAL Therapeutics is a preclinical life sciences company, developing a unique, patented, disease-modifying, small molecule drug platform for the treatment and prevention of Alzheimer’s disease (AD), neurodegenerative conditions and other chronic diseases. The company’s lead drug candidate is a highly selective butyrylcholinesterase (BChE) inhibitor, designed to treat both the symptoms of AD, as well as prevent the neurotoxic cascading pathogenesis of the disease. JAL has conducted two rounds of successful animal testing and is preparing for pre-IND toxicology testing and analysis, investor partnerships, and future pharma licensing. For more information, visit www.JALTherapeutics.com
Media Contact:
Kate Jennings Leahy
Maricich Health
kate.jennings@maricich.com
March 7, 2023—JAL Therapeutics, an Irvine-CA based preclinical stage life sciences company focused on drug development for the treatment of Alzheimer’s disease (AD) and other chronic conditions, has been accepted into the California Life Sciences FAST program.
California Life Sciences (CLS) is the state’s most influential and impactful life sciences membership organization, advocating for companies from startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As an accelerator program by CLS, FAST California fosters innovation by providing a curated advisory team of industry experts for each program member to perfect business models, assess strategic focus, maximize IP and help develop a milestone and scale-up plan to exit.
FAST is supported by sponsors including AbbVie, DLA Piper, Cooley, Hogan Lovells, Johnson & Johnson Innovation, Keck School of Medicine of USC (MESH Academy), MedTech Color, MedTech Innovator, and Women In Bio. Twelve therapeutic and MedTech startups were selected to take part in the FAST California spring cohort, culminating with an event called Innovation Showcase on June 21 in San Francisco. JAL Therapeutics and other companies in the cohort will pitch to an audience of potential investors and collaboration partners at the event.
“It’s an honor for JAL Therapeutics to be in the CLS FAST Advisory program,” said Kensaku Nakayama, CEO. “Our company’s momentum in drug development for AD and other chronic conditions is palpable, and this program will only serve to accelerate our progress. We’re looking forward to collaborating with our advisory team as we refine approaches to engage with strategic investors and potential licensing partners.”
Since its inception, the CLS FAST Advisory Program has been associated with 37 Series A investments among participating startups, totaling $2.5 billion in funds raised. For more information about the California Life Sciences Fast Advisory Program, visit: https://www.califesciences.org/fast-program/
About JAL Therapeutics: JAL Therapeutics is a preclinical life sciences company, developing a unique, patented, disease-modifying, small molecule drug platform for the treatment and prevention of Alzheimer’s disease (AD), neurodegenerative conditions and other chronic diseases. The company’s lead drug candidate is a highly selective butyrylcholinesterase (BChE) inhibitor, designed to treat both the symptoms of AD, as well as prevent the neurotoxic cascading pathogenesis of the disease. JAL has conducted two rounds of successful animal testing and is preparing for pre-IND toxicology testing and analysis, investor partnerships, and future pharma licensing. For more information, visit www.JALTherapeutics.com
Media Contact:
Kate Jennings Leahy
Maricich Health
kate.jennings@maricich.com
